Abstract
Cyclic peptide (arginine-glycine-aspartic-glutamic-valine acid, cRGD)-modified monomethoxy (polyethylene glycol)-poly (D,L-lactide-co-glycolide)-poly (L-lysine) nanoparticles (mPEG-PLGA-PLL-cRGD NPs) with antitumor drug Mitoxantrone (DHAQ) or fluorescence agent Rhodamine B (Rb) encapsulated in their interior were prepared. The remarkable features of the mPEG-PLGA-PLL-cRGD NPs are the effective improvement for the cytotoxicity and uptake of the cell in vitro, and the significant enhancement of delivery ability for DHAQ or Rb in vivo. As a consequence, an excellent therapeutic efficiency for cancer is obtained, demonstrating the mPEG-PLGA-PLL-cRGD NPs play a key role in enhancing cancer therapeutic efficiency.
Crown Copyright © 2012. Published by Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacokinetics
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / drug therapy*
-
Cell Line, Tumor
-
Drug Carriers* / administration & dosage
-
Drug Carriers* / chemistry
-
Female
-
Humans
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Mitoxantrone / administration & dosage
-
Mitoxantrone / chemistry
-
Mitoxantrone / pharmacokinetics
-
Nanoparticles* / administration & dosage
-
Nanoparticles* / chemistry
-
Particle Size
-
Peptides, Cyclic* / administration & dosage
-
Peptides, Cyclic* / chemistry
-
Polyesters* / administration & dosage
-
Polyesters* / chemistry
-
Polyethylene Glycols* / administration & dosage
-
Polyethylene Glycols* / chemistry
-
Polylysine / administration & dosage
-
Polylysine / analogs & derivatives*
-
Polylysine / chemistry
-
Tissue Distribution
Substances
-
Antineoplastic Agents
-
Drug Carriers
-
Peptides, Cyclic
-
Polyesters
-
cyclic arginine-glycine-aspartic acid peptide
-
monomethoxy (polyethylene glycol)-poly(lactide-co-glycolide)-poly(lysine)
-
Polylysine
-
Polyethylene Glycols
-
Mitoxantrone